



Docket No.: 249212US0CONT

IFW

**OBLON**  
**SPIVAK**  
**McCLELLAND**  
**MAIER**  
**&**  
**NEUSTADT**  
**P.C.**

ATTORNEYS AT LAW

NORMAN F. OBLON  
(703) 413-3000  
NOBLON@OBLON.COM

ROLAND E. MARTIN  
(703) 412-6243  
RMARTIN@OBLON.COM  
\*BAR OTHER THAN VIRGINIA

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

RE: Application Serial No.: 10/781,843

Applicants: Munetetsu TEI

Filing Date: February 20, 2004

For: ANTITUMOR AND ANTIVIRAL MEDICATIONS  
AND METHOD FOR PRODUCING THE SAME

Group Art Unit: 1651

Examiner: AFREMOVA, V.

SIR:


Attached hereto for filing are the following papers:

**Restriction Response (3 pp.)**

Our check in the amount of **\$0.00** is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon



Roland E. Martin  
Registration No. 48,082

Customer Number

**22850**

(703) 413-3000 (phone)  
(703) 413-2220 (fax)

DOCKET NO: 249212US0CONT



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF

:

MUNETETSU TEI

: EXAMINER: AFREMOVA, V.

SERIAL NO: 10/781,843

:

FILED: FEBRUARY 20, 2004

: GROUP ART UNIT: 1651

FOR: ANTITUMOR AND ANTIVIRAL  
MEDICATIONS AND METHOD FOR  
PRODUCING THE SAME

:

RESTRICTION RESPONSE

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

This is responsive to the Restriction Requirement dated April 25, 2005.

Applicants elect, with traverse, the claims of Group I, Claims 1-36, for examination.

**Remarks/Arguments** begin on page 2 of this paper.